Sanofi-Aventis U.S. LLC v. Hetero USA Inc.
1:17-cv-00031
Overview
Parties
Defendant
Sanofi Operating Company
Represented By
2 Attorneys ListedRatnerPrestia, P.C.
1007 Orange Street, Suite 205, P.O. Box 1596
RatnerPrestia, P.C.
1007 Orange Street, Suite 205, P.O. Box 1596
Sanofi-Aventis U.S. LLC Operating Company
Represented By
2 Attorneys ListedRatnerPrestia, P.C.
1007 Orange Street, Suite 205, P.O. Box 1596
RatnerPrestia, P.C.
1007 Orange Street, Suite 205, P.O. Box 1596
Plaintiff
Aventisub LLC Operating Company
Represented By
2 Attorneys ListedRatnerPrestia, P.C.
1007 Orange Street, Suite 205, P.O. Box 1596
RatnerPrestia, P.C.
1007 Orange Street, Suite 205, P.O. Box 1596
Genzyme Corporation NPE (Individual / Inventor)
Represented By
2 Attorneys ListedRatnerPrestia, P.C.
1007 Orange Street, Suite 205, P.O. Box 1596
RatnerPrestia, P.C.
1007 Orange Street, Suite 205, P.O. Box 1596
Counter Claimant
Hetero Labs Limited NPE (University / Research)
Represented By
0 Attorneys ListedCourt & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 4 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| π¬π§ United Kingdom | United Kingdom Counterpart | View Official Patent → |
Sanofi-Aventis U.S. LLC v. Emcure Pharmaceuticals Ltd.
Sanofi-Aventis U.S. LLC v. Par Pharmaceutical, Inc.
Sanofi-Aventis U.S. LLC v. Amneal Pharmaceuticals LLC
Sanofi-Aventis U.S. LLC v. Zydus Pharmaceuticals (USA) Inc.
Sanofi-Aventis U.S. LLC v. Mylan Pharmaceuticals Inc.
Sanofi-Aventis U.S. LLC v. MSN Laboratories Private Limited
Sanofi-Aventis U.S. LLC v. Breckenridge Pharmaceutical, Inc.
Sanofi-Aventis U.S. LLC v. Teva Pharmaceuticals USA, Inc.
Sanofi-Aventis U.S. LLC v. Biocon Limited
Patents Involved
There are 3 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US6794410
Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4β²-trifluoromethylphenyl)-amide for treating multiple sclerosis
|
Filed: 2002-04-01
Issued: 2004-09-21
|
Expired (Term Ended)
+1639d PTA
Expires: 2026-09-26
|
|
|
US9186346
Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients
|
Filed: 2014-02-04
Issued: 2015-11-17
|
Active (7.2 yrs remaining)
Expires: 2034-02-04
|
|
|
US8802735
(Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
|
Filed: 2012-03-16
Issued: 2014-08-12
|
Active (5.3 yrs remaining)
Expires: 2032-03-16
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred β Patent expired. Under 35 U.S.C. Β§ 283, injunctive relief is barred.
High PTA (+1639 days) / In re Cellect scrutiny applies.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).